Catalyst Pharmaceuticals (CPRX) Projected to Post Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expected to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.32 per share and revenue of $134.20 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $22.94 on Wednesday. The firm has a market capitalization of $2.74 billion, a price-to-earnings ratio of 19.44, a price-to-earnings-growth ratio of 3.46 and a beta of 0.80. Catalyst Pharmaceuticals has a fifty-two week low of $13.49 and a fifty-two week high of $24.64. The stock’s fifty day moving average is $22.21 and its two-hundred day moving average is $21.19.

Wall Street Analysts Forecast Growth

CPRX has been the topic of a number of analyst reports. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Robert W. Baird initiated coverage on Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price objective on the stock. Truist Financial increased their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $32.25.

Insiders Place Their Bets

In other news, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,500 shares of company stock valued at $1,754,140. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.